Premium
Staphylococcal Infections and Chemotherapy in Children
Author(s) -
Toyonaga Yoshikiyo,
Hori Makoto
Publication year - 1986
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.1986.tb00752.x
Subject(s) - medicine , cefmetazole , cefamandole , fosfomycin , vancomycin , cephalosporin , toxic shock syndrome , coagulase , intensive care medicine , antibiotics , staphylococcus aureus , microbiology and biotechnology , staphylococcus , genetics , bacteria , biology
Staphylococcal infections in childhood are of great inportance. Although serious diseases caused by staphylococci, such as septicemia and meningitis, have been decreasing in recent years, the mortality of these diseases is increasing. In this connection, it should not be overlooked that, in addition to increases in the number of cases with methicillin‐cephem‐resistant S. aureus (MCRSA) and multi‐resistant strains and of cases with acquired immuno‐deficiency due to medical treatment, an increasing emergence of coagulase‐negative staphylococci (CNS) as the etiology, due to such treatments as intratracheal intubation and VP‐shunt, and increases in the number of cases with toxic shock syndrome are encountered. MCRSA, which is at issue in recent years, is in many cases highly resistant, except to minocycline (MINO), fosfomycin (FOM) or vancomycin (VCM). Quite a few strains with good sensitivity to cefmetazole (CMZ) and cefamandole (CMD) of the cephalosporins (CEPs) have been noted. The antibacterial effect of CEPs of groups 1 and 2 including cephalothin (CET) is known to be excellent and likewise the effect of CMZ and MINO has proved also to be excellent. Therefore, in order to cope with the staphylococcal infections in the pediatric field, it is necessary to understand the real status of the resistance of bacteria to chemotherapeutics and aspects at issue in recent years and to take adequate measures from the viewpoint of the host‐parasite drug relationship.